Study in Healthy Volunteers to Examine the Safety, Tolerability and Plasma Pharmacokinetics of One Intramuscular (IM) Injection of a Novel TMC278 LA Formulation at 2 Different Doses (Open Label), Followed by a Placebo-controlled Part of Multiple IM Injections at a Selected Dose (Double Blind).
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2015
At a glance
- Drugs Rilpivirine (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors Janssen R&D Ireland
- 12 Dec 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 12 Dec 2011 Actual initiation date changed from Feb 2010 to Jan 2010 as reported by ClinicalTrials.gov.
- 12 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.